MGTX•MeiraGTx’s third-quarter net loss widened to $51.3 million from $50.5 million a year earlier as research and development costs rose. Revenue increased on higher service revenue from collaborations.
MeiraGTx reported third-quarter net loss of $51.28 million, compared with $50.5 million a year earlier. Revenue rose on increased service revenue from collaborations, while research and development expenses increased with clinical trial and manufacturing activity. Operating expenses were $54.69 million.
The company expects to submit a marketing authorization application for bota-vec to the European Medicines Agency in December 2026 and a full biologics license application to the FDA in the first quarter of 2027. It expects 12-month data from its AAV2-hAQP1 pivotal study in mid-2027.
